AstraZeneca Acquires KuDOS Pharmaceuticals For $210 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
The purchase provides AstraZeneca’s oncology division with DNA repair inhibitors in clinical, preclinical development.
You may also be interested in...
U.K. Newco Raises £6 Mil. To Discover Ubiquitin-Targeting Cancer Drugs
Cancer-focused Mission Therapeutics attracts £6 million Series A, including corporate VC.
U.K. Newco Raises £6 Mil. To Discover Ubiquitin-Targeting Cancer Drugs
Cancer-focused Mission Therapeutics attracts £6 million Series A, including corporate VC.
Pfizer Outlicenses PARP Inhibitor To Clovis
Clovis Oncology will develop and commercialize a PARP inhibitor for solid tumors that was previously being developed by Pfizer.